XtalPi and EDDC collaborate in AI-empowered drug discovery program for Non-Small Cell Lung Cancer
XtalPi joins hands with Singapore’s national platform for drug discovery and development to discover more effective treatment options for cancer patients worldwide
SHENZHEN, China and SINGAPORE, December 19, 2022 /PRNewswire/ — XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, today announced a strategic collaboration with the Experimental Drug Development Center (EDDC). Singapore’s national drug discovery and development platform run by the Agency for Science, Technology and Research of Singapore (A*STAR), to discover new treatment candidates for non-small cell lung cancer (NSCLC).
Lung cancer is the second most common cancer and the leading cause of cancer deaths worldwide. NSCLC accounts for more than 80% of all lung cancer cases and its incidence continues to increase worldwide. The estimated global market size for NSCLC therapeutics will exceed USD20 billion by 2027, according to Research and Markets. Despite increasing interest and investment in drug research, there remains significant unmet need for effective targeted therapy options for NSCLC patients to achieve better outcomes.
In this collaboration, XtalPi joins forces with EDDC to apply its AI technology, automation platform and expert domain knowledge to discover promising candidates against an NSCLC target selected by EDDC. XtalPi will use its quantum physics and AI-driven platform to generate and screen millions of molecules De novo drug design. The predicted top-performing molecules with desired drug properties will be validated and optimized through iterations in its robotics-powered synthesis and testing laboratory. EDDC will provide valuable insight and data on the new NSCLC target, further accelerating the drug discovery process and driving the program towards development.
Dr. Shuhao Wenco-founder and chairman of XtalPi, says: “We are delighted to establish this strategic collaboration with EDDC. XtalPi is committed to serving patients worldwide by advancing the speed, scale, innovation and success rate of drug R&D with AI and automation. Through this partnership, we hope to continue to expand our collaboration with top-tier research institutes in the booming Pan-Asia biotechnology community, drive the rapid translation of new discoveries into much-needed therapies, and contribute to the improved health and longevity of patients Asia and around the world.”
Professor Damian O’ConnellChief Executive Officer of EDDC, says: “We are excited to partner with XtalPi in translating science and research into effective and targeted therapies that enable the treatment of cancer. With XtalPi’s expertise in AI and automation technologies, we are confident that this collaboration will accelerate the development of potential targeted therapy options for NSCLC patients, which is much needed.”
About XtalPi
Founded in 2014, XtalPi founders recognized a common hurdle in drug development related to solid polymorphism, which can be successfully tackled with quantum physics predictions. Since then, XtalPi has maintained its focus on identifying traditional bottlenecks in biopharmaceutical R&D and then attacking them through innovative technologies. Through significant capital investments in automation and staffing, XtalPi now has four locations worldwide and employs approximately 1000 employees. XtalPi is involved in collaborative research with almost all of the top 20 pharmaceutical companies in the world. Its ID4 platform combines physics-based simulations with experimental validation and refinement, automation for rapid synthesis, and machine learning to continuously improve prediction accuracy and process efficiency.
Media contact:
Ruyu Wang
[email protected]
SOURCE XtalPi Inc.
